Skip to content

Early Genetic Identification of Obesity

Whole Genetic Approach in Early Genetic Identification of Obesity (WEGIO)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06239064
Acronym
WEGIO
Enrollment
1000
Registered
2024-02-02
Start date
2024-01-24
Completion date
2027-03-01
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bardet-Biedl Syndrome, Cognitive Impairment, Hyperphagia, Obesity, Childhood, Polydactyly, POMC Deficiency, Retinopathy, Syndactyly

Keywords

Early onset obesity, Hyperphagia, Genetics, Bardet-Biedl Syndrome, LEPR, POMC, PCSK1

Brief summary

TITLE: Whole genetic approach in Early Genetic Identification of Obesity (WEGIO) DESIGN: Multicenter epidemiological study STUDY POPULATION: Participants at risk for a syndromic or a monogenic genetic obesity, incl. participants clinically diagnosed with Bardet-Biedl-Syndrome (BBS) NUMBER OF PARTICIPANTS: 1000 for initial genetic sequencing and app. 40 for the follow-up documentation COORDINATING INVESTIGATOR: Prof. Dr. Arndt Rolfs

Detailed description

TITLE: Whole genetic approach in Early Genetic Identification of Obesity (WEGIO) DESIGN: Multicenter epidemiological study STUDY POPULATION: Participants at risk for a syndromic or a monogenic genetic obesity, incl. participants clinically diagnosed with Bardet-Biedl-Syndrome (BBS) NUMBER OF PARTICIPANTS: 1000 for initial genetic sequencing and app. 40 for the follow-up documentation COORDINATING INVESTIGATOR: Prof. Dr. Arndt Rolfs PARTICIPATING COUNTRY: Germany TREATMENT: Not applicable PRIMARY OBJECTIVE: To investigate the prevalence of BBS in an at-risk population SECONDARY OBJECTIVES: * To explore genotype-phenotype correlation * To assess genotypes distribution in Germany and compare to other countries * To identify new genes/variants * To investigate clinical characteristics in individuals diagnosed with BBS DURATION OF RECRUITMENT: 32 months - total 24 months the recruitment of 1000 subjects 27 months follow up visits 32 months close out of sites INCLUSION CRITERIA: * Informed consent is obtained from the participant/parent/legal guardian * The participant is 2 years of age or older For a participant between 2 and 18 years of age: * The participant has and had a body weight more than 97th percentile before the age of 6 * The participant has one or more of the following symptoms: rod/cone dystrophy, renal abnormalities, ataxia, syndactyly, polydactyly, brachydactyly, hyperphagia, cognitive impairment, speech delay, hypogonadism For a participant who is 18 years of age or older: * The participant has BMI ≥ 30 kg/m2 * The participant had a body weight more than 97th percentile before the age of 6 years * The participant has rod/cone dystrophy * The participant is 2 or more years of age, is clinically diagnosed with Bardet-Biedl-Syndrome (BBS) or is a sibling of an individual diagnosed with BBS via the WEGIO study

Interventions

DIAGNOSTIC_TESTGenetic testing via blood collection

blood collection

Sponsors

Rhythm Pharmaceuticals, Inc.
CollaboratorINDUSTRY
Rolfs Consulting und Verwaltungs-GmbH (RCV)
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum

Inclusion criteria

* Informed consent is obtained from the participant/parent/legal guardian * The participant is 2 years of age or older For a participant between 2 and 18 years of age: * The participant has and had a body weight more than 97th percentile before the age of 6 * The participant has one or more of the following symptoms: rod/cone dystrophy, renal abnormalities, ataxia, syndactyly, polydactyly, brachydactyly, hyperphagia, cognitive impairment, speech delay, hypogonadism For a participant who is 18 years of age or older: * The participant has BMI ≥ 30 kg/m2 * The participant had a body weight more than 97th percentile before the age of 6 years * The participant has rod/cone dystrophy * The participant is 2 or more years of age, is clinically diagnosed with Bardet-Biedl-Syndrome (BBS) or is a sibling of an individual diagnosed with BBS via the WEGIO study

Exclusion criteria

\- Not fulfilling the inclusion criteria

Design outcomes

Primary

MeasureTime frameDescription
BBS prevalence2 yearsTo investigate the prevalence of BBS in patients suspected to a genetic obesity

Secondary

MeasureTime frameDescription
Phenotypic and genetic characterization2 yearsTo understand the genotype-phenotype correlation; to assess genotypes distribution in Germany and compare to other countries; to identify new genes/variants; to investigate clinical characteristics in individuals diagnosed with BBS

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026